Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist w...

Full description

Bibliographic Details
Main Authors:	Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, Melanie J. Davies
Format:	Article
Language:	English
Published:	Korean Society for the Study of Obesity 2023-03-01
Series:	Journal of Obesity & Metabolic Syndrome
Subjects:	diabetes mellitus type 2 obesity tirzepatide glucagon-like peptide 1 gastric inhibitory polypeptide
Online Access:	http://www.jomes.org/journal/view.html?doi=10.7570/jomes22067

Similar Items

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023-04-01)

Tirzepatide for type 2 diabetes
by: Sarah L Anderson, et al.
Published: (2023-08-01)

Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent
by: ZHANG Lina, WANG Yan, ZHANG Kanghuai, LI Youjia
Published: (2023-05-01)

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
by: Razzaki TS, et al.
Published: (2022-09-01)

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
by: Rouchan Ali, et al.
Published: (2022-09-01)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
by: Alekya Devi Anala, et al.
Published: (2023-07-01)

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
by: Eonju Jeon, et al.
Published: (2023-06-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
by: Alexandros Leonidas Liarakos, et al.
Published: (2023-07-01)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01)

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
by: Qingyue Zeng, et al.
Published: (2023-10-01)

Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
by: Qingyue Zeng, et al.
Published: (2024-03-01)

Glucose-Dependent Insulinotropic Peptide Level Is Associated with the Development of Type 2 Diabetes Mellitus
by: Sunghwan Suh, et al.
Published: (2016-03-01)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
by: Han Na Jung, et al.
Published: (2022-03-01)

Tirzepatide-induced ketoacidosis in non-diabetic patients
by: Pathan Mohamad Rafe Iqbal, et al.
Published: (2024-03-01)

DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus
by: Shao Y, et al.
Published: (2024-04-01)

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
by: Vivek P. Chavda, et al.
Published: (2022-07-01)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
by: Zhuqing Meng, et al.
Published: (2023-03-01)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
by: Nicholas Chiu, et al.
Published: (2022-08-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus
by: Soyeon Yoo, et al.
Published: (2019-08-01)

Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer’s Disease
by: Jelena Osmanovic Barilar, et al.
Published: (2022-01-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes
by: Kozlovski P, et al.
Published: (2017-03-01)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
by: Baptist Gallwitz
Published: (2022-10-01)

Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
by: Wenting Cai, et al.
Published: (2024-01-01)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
by: Soyeon Yoo, et al.
Published: (2021-06-01)

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
by: Pejman Rohani, et al.
Published: (2023-08-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023-12-01)

Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis
by: Ruifang Guan, et al.
Published: (2022-10-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
by: Yusuke Seino, et al.
Published: (2022-07-01)

Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis
by: Yanan Ding, et al.
Published: (2024-01-01)

G protein-coupled receptors and obesity
by: Alessandro Pocai
Published: (2023-12-01)

Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review
by: Akira Mima, et al.
Published: (2023-09-01)

Gut microbiota is an endocrine organ
by: Tatiana Y. Demidova, et al.
Published: (2020-12-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

CORRELATION BETWEEN PRE AND POSTOPERATIVE LEVELS OF GLP-1/GLP-2 AND WEIGHT LOSS AFTER ROUX-EN-Y GASTRIC BYPASS: A PROSPECTIVE STUDY
by: Everton CAZZO, et al.
Published: (2016-12-01)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)